C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma
Showing 1 - 25 of >10,000
Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston
Not yet recruiting
- Refractory Aggressive B-cell Lymphomas
- +12 more
- ACALABRUTINIB
- +2 more
-
Boston, Massachusetts
- +1 more
Oct 13, 2022
High-grade B-cell Lymphoma, Burkitt Lymphoma, Lymphoma, B-Cell Trial in Busan, Seoul (Sepantronium Bromide)
Not yet recruiting
- High-grade B-cell Lymphoma
- +8 more
- Sepantronium Bromide
-
Busan, Korea, Republic of
- +5 more
Feb 27, 2022
DLBCL, High Grade B-Cell Lymphoma w/MYC & BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma w/MYC, BCL2 & BCL6
Recruiting
- Diffuse Large B-Cell Lymphoma
- +2 more
- Prednisone
- +6 more
-
Tampa, Florida
- +1 more
Jan 12, 2022
Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia Trial in Houston
Recruiting
- Recurrent Acute Lymphoblastic Leukemia
- +10 more
- Bortezomib
- +8 more
-
Houston, TexasM D Anderson Cancer Center
Sep 21, 2022
Recurrent DLBCL Activated B-Cell Type, Recurrent DLBCL Germinal Center B-Cell Type, Recurrent High Grade B-Cell Lymphoma With
Recruiting
- Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type
- +8 more
- Biospecimen Collection
- +3 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Mar 8, 2023
Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma
Not yet recruiting
- Double-Expressor Lymphoma
- +3 more
- Cyclophosphamide
- +6 more
-
Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
Oct 27, 2022
Non Hodgkin Lymphoma, Lymphoma, B-Cell, High-grade B-cell Lymphoma Trial in Belgium, Netherlands (DA-EPOCH-R followed by
Active, not recruiting
- Non Hodgkin Lymphoma
- +4 more
- DA-EPOCH-R followed by Nivolumab
-
Antwerpen, Belgium
- +23 more
Mar 23, 2022
Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic Hodgkin Lymphoma, Recurrent
Not yet recruiting
- Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
- +21 more
- Biopsy
- +8 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Apr 7, 2023
Recurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between
Not yet recruiting
- Recurrent ALK Positive Large B-Cell Lymphoma
- +28 more
- Biospecimen Collection
- +5 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Aug 17, 2022
Diffuse Large B-cell Lymphoma, High-Grade B-cell Lymphoma Trial in Worldwide (RO6870810, Venetoclax, Rituximab)
Completed
- Diffuse Large B-cell Lymphoma
- High-Grade B-cell Lymphoma
- RO6870810
- +2 more
-
Duarte, California
- +8 more
Jan 21, 2022
ALK-Positive Large B-Cell Lymphoma, Burkitt-Like Lymphoma With 11q Aberration, DLBCL Activated B-Cell Type Trial in United
Active, not recruiting
- ALK-Positive Large B-Cell Lymphoma
- +34 more
- Nivolumab
- Varlilumab
-
Phoenix, Arizona
- +32 more
Jan 3, 2023
Recurrent DLBCL, Recurrent DLBCL, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6
Withdrawn
- Recurrent Diffuse Large B-Cell Lymphoma
- +9 more
- Autologous Hematopoietic Stem Cell Transplantation
- +5 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 11, 2023
Phase 1, NSCLC, SCLC Trial in United States (Oral MRT-2359)
Recruiting
- NSCLC
- +6 more
- Oral MRT-2359
-
Scottsdale, Arizona
- +7 more
Dec 20, 2022
Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate
Recruiting
- Aggressive Non-Hodgkin Lymphoma
- +8 more
- Polatuzumab Vedotin
- +6 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 26, 2023
Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6
Not yet recruiting
- Grade 3b Follicular Lymphoma
- +5 more
- Biospecimen Collection
- +9 more
- (no location specified)
Jun 6, 2023
Ann Arbor Stage III DLBCL, Ann Arbor Stage IIX (Bulky) DLBCL, Ann Arbor Stage IV DLBCL Trial in United States (drug, other,
Suspended
- Ann Arbor Stage III Diffuse Large B-Cell Lymphoma
- +20 more
- Cyclophosphamide
- +6 more
-
Tucson, Arizona
- +110 more
Jan 31, 2023
Ann Arbor Stage II DLBCL, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma Trial in Scottsdale,
Recruiting
- Ann Arbor Stage II Diffuse Large B-Cell Lymphoma
- +13 more
- Cyclophosphamide
- +6 more
-
Scottsdale, Arizona
- +2 more
Jun 1, 2022
High Grade B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements,
Recruiting
- High Grade B-Cell Lymphoma, Not Otherwise Specified
- +4 more
- Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX
- R-CHOP; R-DA-EPOCH; R-HD MTX
-
Jinan, Shandong, ChinaDepartment of Hematology, Shandong Provincial Hospital
Dec 7, 2021
B-Cell Non-Hodgkin Lymphoma, DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma Trial in Seattle (Acalabrutinib,
Recruiting
- B-Cell Non-Hodgkin Lymphoma
- +7 more
- Acalabrutinib
- Axicabtagene Ciloleucel
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Dec 9, 2022
High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified,
Recruiting
- High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
- +4 more
- Orelabrutinib+R-CHOP; Orelabrutinib+R-DA-EPOCH; Orelabrutinib+R-HD MTX;Orelabrutinib+R+other chemotherapies
-
Jinan, Shandong, ChinaShandong Provincial Hospital
Nov 18, 2021
Aggressive Non-Hodgkin Lymphoma, Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Ann Arbor Stage II
Active, not recruiting
- Aggressive Non-Hodgkin Lymphoma
- +13 more
- Cyclophosphamide
- +6 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Aug 18, 2022
DLBCL, Not Otherwise Specified, Recurrent DLBCL, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial in Seattle
Terminated
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- +5 more
- Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014
- +3 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Aug 1, 2022
Hematopoietic and Lymphoid Cell Tumor, Recurrent DLBCL, Recurrent High Grade B-Cell Lymphoma Trial in Houston (Anakinra,
Active, not recruiting
- Hematopoietic and Lymphoid Cell Neoplasm
- +8 more
- Anakinra
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Aug 22, 2022